Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancer

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Valdés Mora, Fátima ^a,b   Gould, Cathryn M ^a   Colino Sanguino, Yolanda ^a   Qu, Wenjia ^a   Song, Jenny Z ^a   Taylor, Kylie M ^a   Buske, Fabian A ^a   Statham, Aaron L ^a   Nair, Shalima S ^a,b   Armstrong, Nicola J ^c   Kench, James G ^a,d,e   Lee, Kenneth M L ^e,f   Horvath, Lisa G ^a,e,g   Qiu, Minru ^h   Ilinykh, Alexei ^a   Yeo Teh, Nicole S ^a   Gallego Ortega, David ^a,b   Stirzaker, Clare ^a,b   Clark, Susan J ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c MURDOCH UNIVERSITY   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f Department of Microbiology and Infectious Diseases   (Australia)

^g Chris O'Brien Lifehouse   (Australia)

^h ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; DOXYCYCLINE; HISTONE H2AZ; AR PROTEIN, HUMAN; HISTONE; HISTONE H2A.F-Z;

ACETYLENE; ANDROGEN; CANCER; CORRELATION; GENE EXPRESSION;

ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA METHYLATION; ECTOPIC EXPRESSION; ENHANCER REGION; EPIGENETICS; GENE ACTIVATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LNCAP CELL LINE; MAJOR CLINICAL STUDY; MALE; NPREC CELL LINE; NUCLEOSOME; PROMOTER REGION; PROSTATE CANCER; PROSTATECTOMY; VCAP CELL LINE; ACETYLATION; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; MORTALITY; PROSTATE TUMOR;

ACETYLATION; CHROMATIN; DISEASE-FREE SURVIVAL; ENHANCER ELEMENTS, GENETIC; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; MALE; NUCLEOSOMES; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 85033400672     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-01393-8     Document Type: Article

References (70)

1. Kamakaka, R. T. & Biggins, S. Histone variants: deviants? Genes Dev. 19, 295-310, https://doi.org/10.1101/gad.1272805 (2005).
2. Zlatanova, J. & Thakar, A. H2A.Z: view from the top. Structure 16, 166-179 (2008).
3. Sevilla, A. & Binda, O. Post-translational modifications of the histone variant H2AZ. Stem Cell Res. 12, 289-295, https://doi.org/10.1016/j.scr.2013.11.004 (2014).
4. Bruce, K. et al. The replacement histone H2A.Z in a hyperacetylated form is a feature of active genes in the chicken. Nucleic Acids Res. 33, 5633-5639 (2005).
5. Valdes-Mora, F. et al. Acetylation of H2A.Z is a key epigenetic modification associated with gene deregulation and epigenetic remodeling in cancer. Genome Res. 22, 307-321 (2012).
6. Ishibashi, T. et al. Acetylation of vertebrate H2A.Z and its effect on the structure of the nucleosome. Biochemistry 48, 5007-5017, https://doi.org/10.1021/bi900196c (2009).
7. Vardabasso, C. et al. Histone variants: emerging players in cancer biology. Cell Mol. Life. Sci. 71, 379-404, https://doi.org/10.1007/s00018-013-1343-z (2014).
8. Draker, R., Sarcinella, E. & Cheung, P. USP10 deubiquitylates the histone variant H2A.Z and both are required for androgen receptor-mediated gene activation. Nucleic Acids Res. 39, 3529-3542 (2011).
9. Dryhurst, D., McMullen, B., Fazli, L., Rennie, P. S. & Ausio, J. Histone H2A.Z prepares the prostate specific antigen (PSA) gene for androgen receptormediated transcription and is upregulated in a model of prostate cancer progression. Cancer Lett. 315, 38-47 (2012).
10. Abraham, B. J., Cui, K., Tang, Q. & Zhao, K. Dynamic regulation of epigenomic landscapes during hematopoiesis. BMC Genomics 14, 193 (2013).
11. Hu, G. et al. H2A.Z facilitates access of active and repressive complexes to chromatin in embryonic stem cell self-renewal and differentiation. Cell Stem Cell 12, 180-192 (2013).
12. Ku, M. et al. H2A.Z landscapes and dual modifications in pluripotent and multipotent stem cells underlie complex genome regulatory functions. Genome Biol. 13, R85 (2012).
13. Jin, C. et al. H3.3/H2A.Z double variant-containing nucleosomes mark 'nucleosome-free regions' of active promoters and other regulatory regions. Nat. Genet. 41, 941-945 (2009).
14. Heintzman, N. D. et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 459, 108-112 (2009).
15. Brunelle, M. et al. The histone variant H2A.Z is an important regulator of enhancer activity. Nucleic Acids Res., https://doi.org/10.1093/nar/gkv825 (2015).
16. He, H. H. et al. Nucleosome dynamics define transcriptional enhancers. Nat. Genet. 42, 343-347 (2010).
17. Wang, Q. et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol. Cell 27, 380-392, https://doi.org/10.1016/j.molcel.2007.05.041 (2007).
18. Wang, D. et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 474, 390-394 (2011).
19. Ren, Q. & Gorovsky, M. A. Histone H2A.Z acetylation modulates an essential charge patch. Mol. Cell 7, 1329-1335 (2001).
20. Ernst, J. & Kellis, M. ChromHMM: automating chromatin-state discovery and characterization. Nat. Methods 9, 215-216 (2012).
21. Taberlay, P. C., Statham, A. L., Kelly, T. K., Clark, S. J. & Jones, P. A. Reconfiguration of nucleosome-depleted regions at distal regulatory elements accompanies DNA methylation of enhancers and insulators in cancer. Genome Res. 24, 1421-1432 (2014).
22. Lun, A. T. & Smyth, G. K. De novo detection of differentially bound regions for ChIP-seq data using peaks and windows: controlling error rates correctly. Nucleic Acids Res. 42, e95 (2014).
23. Suzuki, H., Ueda, T., Ichikawa, T. & Ito, H. Androgen receptor involvement in the progression of prostate cancer. Endocr. Relat. Cancer 10, 209-216 (2003).
24. Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22 (2010).
25. Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R. & Verma, I. M. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 274, 787-789 (1996).
26. Kelly, T. K. et al. Genome-wide mapping of nucleosome positioning and DNA methylation within individual DNA molecules. Genome Res. 22, 2497-2506 (2012).
27. Holzbeierlein, J. et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am. J. Pathol. 164, 217-227 (2004).
28. Masser, D. R., Berg, A. S. & Freeman, W. M. Focused, high accuracy 5-methylcytosine quantitation with base resolution by benchtop next-generation sequencing. Epigenet. Chromatin 6, 33 (2013).
29. Andreu-Vieyra, C. et al. Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells. Mol. Cell Biol. 31, 4648-4662 (2011).
30. Heemers, H. V. & Tindall, D. J. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr. Rev. 28, 778-808 (2007).
31. Wang, R. et al. Role of transcriptional corepressor CtBP1 in prostate cancer progression. Neoplasia 14, 905-914 (2012).
32. Takayama, K. et al. CtBP2 modulates the androgen receptor to promote prostate cancer progression. Cancer Res. 74, 6542-6553 (2014).
33. Zhao, J. C. et al. FOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression. Oncogene 35, 4335-4344 (2016).
34. De Santa, F. et al. A large fraction of extragenic RNA pol II transcription sites overlap enhancers. PLoS Biol 8, e1000384 (2010).
35. Stewart, B. W., Wild, C. World Cancer Report 2014. World Health Organization (International Agency for Research on Cancer,. WHO Press, 2014).
36. Dalvai, M. et al. H2A.Z-dependent crosstalk between enhancer and promoter regulates Cyclin D1 expression. Oncogene, https://doi.org/10.1038/onc.2012.442 (2012).
37. Dalvai, M., Fleury, L., Bellucci, L., Kocanova, S. & Bystricky, K. TIP48/Reptin and H2A.Z requirement for initiating chromatin remodeling in estrogenactivated transcription. PLoS. Genet. 9, e1003387 (2013).
38. Cheng, Y. et al. Genome-wide analysis of androgen receptor binding sites in prostate cancer cells. Exp. Ther. Med. 9, 2319-2324 (2015).
39. Hsieh, C. L. et al. Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation. Proc. Natl Acad. Sci. USA 111, 7319-7324 (2014).
40. Chen, Z. et al. Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth. EMBO J. 30, 2405-2419 (2011).
41. Murakawa, Y. et al. Enhanced identification of transcriptional enhancers provides mechanistic insights into diseases. Trends Genet. 32, 76-88 (2016).
42. Jia, L. et al. Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genet. 5, e1000597 (2009).
43. Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934-947 (2013).
44. Vardabasso, C. et al. Histone variant H2A.Z.2 mediates proliferation and drug sensitivity of malignant melanoma. Mol. Cell 59, 75-88 (2015).
45. Draker, R. et al. A combination of H2A.Z and H4 acetylation recruits Brd2 to chromatin during transcriptional activation. PLoS Genet. 8, e1003047 (2012).
46. Asangani, I. A. et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510, 278-282 (2014).
47. Korenchuk, S. et al. VCaP, a cell-based model system of human prostate cancer. In Vivo 15, 163-168 (2001).
48. Gray, D. C. et al. pHUSH: a single vector system for conditional gene expression. BMC Biotechnol 7, 61 (2007).
49. Morita, S., Kojima, T. & Kitamura, T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 7, 1063-1066 (2000).
50. Brummer, T. et al. Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein. J. Biol. Chem. 281, 626-637 (2006).
51. Horvath, L. G. et al. Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer. Int. J. Cancer 113, 415-422 (2005).
52. Kononen, J. et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 4, 844-847 (1998).
53. Hua, S. et al. Genomic analysis of estrogen cascade reveals histone variant H2A. Z associated with breast cancer progression. Mol. Syst. Biol. 4, 188 (2008).
54. Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memoryefficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
55. Feng, X., Grossman, R. & Stein, L. PeakRanger: a cloud-enabled peak caller for ChIP-seq data. BMC Bioinf. 12, 139 (2011).
56. Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).
57. Li, Q., Brown, J. B., Huang, H. & Bickel, P. J. Measuring reproducibility of highthroughput experiments. Ann. Appl. Stat. 5, 1752-1779 (2011).
58. Lun, A. T. & Smyth, G. K. csaw: a Bioconductor package for differential binding analysis of ChIP-seq data using sliding windows. Nucleic Acids Res., https://doi.org/10.1093/nar/gkv1191 (2015).
59. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).
60. Shen, L., Shao, N., Liu, X. & Nestler, E. ngs.plot: Quick mining and visualization of next-generation sequencing data by integrating genomic databases. BMC Genomics 15, 284 (2014).
61. Heger, A., Webber, C., Goodson, M., Ponting, C. P. & Lunter, G. GAT: a simulation framework for testing the association of genomic intervals. Bioinformatics 29, 2046-2048 (2013).
62. Ernst, J. et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 473, 43-49 (2011).
63. Pedersen, B. S., Eyring, K., De, S., Yang, I. V. & Schwartz, D. A. Fast and accurate alignment of long bisulfite-seq reads. arXiv:1401.1129 [q.bio.GN] (2014).
64. Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv:1303.3997 [q-bio.GN], 1-3 (2013).
65. Liu, Y., Siegmund, K. D., Laird, P. W. & Berman, B. P. Bis-SNP: combined DNA methylation and SNP calling for Bisulfite-seq data. Genome Biol. 13, R61 (2012).
66. Clark, S. J., Statham, A., Stirzaker, C., Molloy, P. L. & Frommer, M. DNA methylation: bisulphite modification and analysis. Nat. Protoc. 1, 2353-2364 (2006).
67. Lee, H. J. et al. Lineage specific Methylation of the Elf5 promoter in mammary epithelial cells. Stem Cells, https://doi.org/10.1002/stem.706 (2011).
68. Simandi, Z., Horvath, A., Nagy, P. & Nagy, L. Prediction and validation of gene regulatory elements activated during retinoic acid induced embryonic stem cell differentiation. J. Vis. Exp., https://doi.org/10.3791/53978 (2016).
69. Carvalho, B. S. & Irizarry, R. A. A framework for oligonucleotide microarray preprocessing. Bioinformatics 26, 2363-2367 (2010).
70. Ritchie, M. E. et al. limma powers differential expression analyses for RNAsequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).